Compare UI & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UI | ONC |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8B | 34.8B |
| IPO Year | 2011 | N/A |
| Metric | UI | ONC |
|---|---|---|
| Price | $562.20 | $308.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $587.50 | $369.50 |
| AVG Volume (30 Days) | 85.1K | ★ 271.1K |
| Earning Date | 02-06-2026 | 11-06-2025 |
| Dividend Yield | ★ 0.58% | N/A |
| EPS Growth | ★ 102.50 | N/A |
| EPS | ★ 13.07 | 0.58 |
| Revenue | $2,756,974,000.00 | ★ $4,972,687,000.00 |
| Revenue This Year | $15.29 | $895.40 |
| Revenue Next Year | $8.93 | $22.04 |
| P/E Ratio | ★ $42.34 | $519.59 |
| Revenue Growth | 36.77 | ★ 50.43 |
| 52 Week Low | $255.00 | $172.67 |
| 52 Week High | $803.60 | $385.22 |
| Indicator | UI | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 45.52 | 41.49 |
| Support Level | $553.34 | $302.14 |
| Resistance Level | $572.45 | $310.88 |
| Average True Range (ATR) | 15.42 | 6.35 |
| MACD | 2.50 | -0.23 |
| Stochastic Oscillator | 58.51 | 37.87 |
Ubiquiti Inc is a seller of equipment and provides the related software platforms through web stores. The group develops technology platforms for high-capacity distributed Internet access, unified information technology, and consumer electronics for professional, home, and personal use. Its solutions are: high-performance networking technology for enterprises, service providers, and consumers. target the enterprise and service provider markets through a community of service providers, distributors, value-added resellers, webstores, systems integrators, and corporate IT professionals, which it refers to as the Ubiquiti Community. It targets consumers through digital marketing, including through webstores, retail chains, and, to a lesser extent, the Ubiquiti Community.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.